UPDATE: Jefferies Assumes Coverage on Nanosphere at Buy Awaiting Gram-Positive Ramp

Loading...
Loading...

In a report published Friday, Jefferies analyst Brandon Couillard assumed coverage on Nanosphere NSPH with a Buy rating, and raised the price target from $3.50 to $5.50.

In the report, Jefferies noted, “Aided by its first mover-advantage status, we expect NSPH's proprietary gram-positive blood stream infection test to drive significant new system placements and revenue growth over the next several years. Assuming coverage at Buy / $5.50 price target.”

Nanosphere closed on Thursday at $3.88.

Market News and Data brought to you by Benzinga APIs
Posted In: Analyst ColorInitiationAnalyst RatingsBrandon CouillardJefferies
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...